Updated on 14 October 2016
Boehringer Ingelheim announces that it would return the drug‘s development and commercialization rights
Singapore: New blockbuster cancer drug from South Korea's Hanmi pharmaceuticals is in troubled waters after a patient died of a severe skin-related side effect linked to the drug's use.
Hanmi's lung cancer drug Olmutinib, also known as HM61713 or BI148294, is a third-generation lung cancer therapy for patients who have developed a tolerance to existing lung cancer treatments.
Further to add to the woes, Hanmi's licensing partner Boehringer Ingelheim announced that it would return the drug‘s development and commercialization rights it had purchased from the Korean drugmaker in July 2015 in a deal valued at $730 million.
As per the Korean Herald, the Korean Ministry of Food and Drug Safety has prohibited doctors from prescribing Olmutinib to new patients and warned patients already using Olmutinib to "use the drug with caution" in consultation with doctors, citing three cases of life-threatening side effects linked to the drug's use during clinical trials.
The ministry officials will meet up to decide on the causal relationship between the drug and the given side effects to determine its next moves, which could include completely banning the drug's sales, Yonhap News Agency reported.